Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

Benjamin Daniels; Sarah J Lord; Belinda E Kiely; Nehmat Houssami; Philip Haywood; Christine Y Lu; Robyn L Ward; Sallie-Anne Pearson

doi:10.1136/bmjopen-2016-014439

Article info

PDF

XML

Oncology

Protocol

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

Authors

Benjamin Daniels Medicines Policy Research Unit, Centre for Big Data Research in Health, UNSW, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Sarah J Lord School of Medicine, University of Notre Dame Australia, Sydney, New South Wales, Australia NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Belinda E Kiely NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Nehmat Houssami Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Philip Haywood Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Christine Y Lu Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA PubMed articles Google scholar articles
Robyn L Ward University of Queensland, Brisbane, Queensland, Australia PubMed articles Google scholar articles
Sallie-Anne Pearson Medicines Policy Research Unit, Centre for Big Data Research in Health, UNSW, Sydney, New South Wales, Australia PubMed articles Google scholar articles

Correspondence to Professor Sallie-Anne Pearson; sallie.pearson{at}unsw.edu.au

View Full Text

Citation

Daniels B, Lord SJ, Kiely BE On behalf of the HER2 therapy observational study (HER2-OBS) investigators, et al

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

BMJ Open 2017;7:e014439. doi: 10.1136/bmjopen-2016-014439

Publication history

Received September 27, 2016
Revised December 22, 2016
Accepted December 29, 2016
First published January 24, 2017.

Online issue publication

November 28, 2017

Previous versions

Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password